Treating muc1-expressing cancers with helicase inhibitors
AssigneeDana-Farber Cancer Institute, Inc.
InventorDonald Kufe
Life of this patent
Estimating the term…
Abstract
The invention provides method of treating cancers that express MUC1 by the administration of eIF4A helicase inhibitors. These inhibitors may advantageously be combined with peptides that inhibit MUC1 oligomerization, or with other standard anticancer therapies such as chemo-, radio- and surgical therapies.
Claims32
A method of inhibiting a cancer cell that expresses MUC1 comprising contacting said cancer cell with an inhibitor of eIF4A RNA helicase.
(canceled)
10-15. (canceled)
A method of treating MUC1-expressing cancer in a subject comprising administering to said subject an inhibitor of eIF4A RNA helicase.
(canceled)
26-28. (canceled)
30-35. (canceled)
(canceled)
40-45. (canceled)
47-48. (canceled)
A kit comprising (a) a MUC1 detection agent and (b) and eIF4A inhibitor.
(canceled)
Dependencies are inferred from the claim text.